Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
The filing shows a planned sale of 20,000 shares of Merck (MRK) common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of 2,368,202.00. Merck had 2,482,022,536 common shares outstanding at the time of this notice.
The seller, identified as Chirfi Guindo, previously sold 20,000 common shares on 02/05/2026 for gross proceeds of 2,437,676.00. The shares to be sold were acquired through restricted stock vesting under a registered plan on several dates between 08/03/2023 and 01/27/2025. By signing, the seller represents they are not aware of undisclosed material adverse information about Merck.
Merck & Co., Inc.’s Chief Marketing Officer, Chirfi Guindo, reported an open-market sale of company stock. On 02/12/2026, he sold 10,000 shares of Merck common stock at a weighted average price of $121.4562 per share, through multiple trades in a narrow price range.
After this transaction, Guindo directly beneficially owned 60,615.127 shares of Merck common stock. The filing notes that detailed trade-by-trade pricing within the $121.4400 to $121.5150 range is available upon request.
Merck & Co. insider transaction notice: A person filing for Merck (MRK) plans to sell 10,235 common shares through Morgan Stanley Smith Barney LLC on or about 02/10/2026 on the NYSE, with an aggregate market value of 1202843.81.
The shares to be sold were acquired as restricted stock vesting under a registered plan on 01/26/2026, in the same amount of 10,235 shares. Over the past three months, an individual named Dean Li sold 15,087 Merck common shares on 02/04/2026 for gross proceeds of 1791824.15.
Merck & Co., Inc. Executive VP & President, MRL, Dean Y. Li reported an open-market sale of common stock. On February 10, 2026, he sold 10,235 shares of Merck common stock at a weighted average price of $117.5226 per share.
After this transaction, Li beneficially owned 92,035.05 shares of Merck common stock in direct form. The sale was executed through multiple trades within a price range of $117.5200 to $117.5550, with the reported price reflecting the weighted average across those trades.
A shareholder of MRK has filed a Form 144 indicating an intention to sell 121,573 shares of common stock on the NYSE. The planned sale, through Morgan Stanley Smith Barney LLC, has an aggregate market value of $14,485,690.41.
The shares were acquired on 02/09/2026 by exercising stock options under a registered plan, with the purchase price paid in cash on the same date. The filing notes that 2,482,022,536 shares of the issuer’s common stock were outstanding, providing context for the size of the proposed sale.
Merck & Co. insider plans stock sale under Rule 144. A person named Chirfi Guindo filed to sell 20,000 shares of Merck common stock through Morgan Stanley Smith Barney LLC on or around 02/09/2026 on the NYSE, with an aggregate market value of $2,368,202.00.
The 20,000 shares were acquired on 08/03/2023 via restricted stock vesting under a registered plan. Over the past three months, the same seller disposed of another 20,000 Merck shares on 02/05/2026 for gross proceeds of $2,437,676.00. Merck had 2,482,022,536 shares outstanding. The seller represents awareness of no undisclosed material adverse information.
Merck & Co., Inc. Chief Marketing Officer Chirfi Guindo reported selling 10,000 shares of Merck common stock on 02/09/2026. The sale was executed at a weighted average price of $118.4101 per share, with individual trades ranging from $118.4000 to $118.4502. After this transaction, Guindo beneficially owns 70,615.127 shares of Merck common stock directly.
Merck & Co., Inc. executive vice president and general counsel Jennifer Zachary reported option exercises and related share sales in company stock. On 02/09/2026, she exercised three stock option grants covering 25,946, 56,792 and 38,835 shares of common stock, which had previously vested in scheduled installments. On the same date, she sold corresponding amounts of Merck common shares at a weighted average price of $119.1522 per share, with individual sale prices ranging from $118.9600 to $119.5100. Following these transactions, she directly held 68,915.671 shares of Merck common stock.
A shareholder has filed a notice of proposed sale of 37,685 shares of common stock, with an aggregate market value of $4,557,024.71. The shares are expected to be sold on or about 02/06/2026 on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.
The securities to be sold were acquired as restricted stock vesting under a registered plan from the issuer on several dates in 2024, including 21,845 shares on 01/22/2024 and 13,766 shares on 05/04/2024. By signing the notice, the selling person represents they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
An insider of the issuer has filed a Form 144 notice to sell 5,000 shares of common stock. The planned sale, through Morgan Stanley Smith Barney LLC on the NYSE, has an aggregate market value of $609,525.00 and an approximate sale date of February 6, 2026.
The 5,000 shares were acquired on February 6, 2026 by exercising options under a registered plan, paid for in cash. The filing notes that 2,482,022,536 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.